Telomir Pharmaceuticals, Inc. (market cap: $117.85M), a Florida-based biopharmaceutical company, today reported significant preclinical results for its investigational drug Telomir-1, showing promise in reversing key parameters of Type 2 diabetes.
The study, conducted in collaboration with Pentagrit, assessed the efficacy of Telomir-1 in oral formulations across different dosing regimens. Results indicated a dose-dependent normalization of blood glucose, enhanced glucose metabolism, and a notable decrease in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) scores, a measure of insulin sensitivity.
The key outcomes of the research include the reversal of insulin resistance, improved glucose clearance as evidenced by Oral Glucose Tolerance Tests (OGTT), and increased survival rates among the treated models. These results position Telomir-1 as a potentially transformative agent in the management of Type 2 diabetes.
Telomir-1 operates through a novel mechanism, targeting iron metabolism linked to oxidative stress and beta-cell damage, which are underlying contributors to Type 2 diabetes. By normalizing iron homeostasis, the drug could address the root causes of the condition.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.